There is a lot of outrage that the new Alzheimer’s drug donanemab is being refused on the NHS. But there are good reasons for ...

Two novel drugs for treating Alzheimer's have been rejected for use on the NHS, despite gaining approval from the UK ...

Add Alzheimer's disease to the list of conditions that might benefit from the revolutionary diabetes drug Ozempic, a new ...

A new study shows that a common glaucoma drug cleared tau build-up and reduced signs of neurodegenerative disease in zebrafish and mice.

Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

Add Alzheimer's disease to the list of conditions that might benefit from the revolutionary diabetes drug Ozempic, a new study says. People with Type 2 diabetes taking semaglutide appeared to have ...

This year has seen several biopharma companies drop Alzheimer’s and Parkinson’s disease programs, but experts say plenty are ...

Type 2 diabetics taking the drug had a lower risk of Alzheimer’s compared to patients on other diabetes drugs Semaglutide is ...

For the second time in recent months, a U.K. agency said the limited benefits of a new Alzheimer’s drug do not justify its ...

On average, patients with Alzheimer disease and related dementias spend $1199.70 per year on out-of-pocket prescription drug costs.

In the effort to expand approaches to treating Alzheimer’s beyond targeting amyloid, some companies have sought to target ...

Lilly’s solanezumab famously failed to produce significant results in early stage Alzheimer’s late last year, the latest in a long list of drugs that have come up short in trials. George ...